Results 61 to 70 of about 70,663 (209)

New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer [PDF]

, 2012
A summit on cellular therapy for cancer discussed and presented advances related to the use of adoptive cellular therapy for melanoma and other cancers. The summit revealed that this field is advancing rapidly.
A Lundqvist, A Somers, C Berger, CA Tran, Carolina Berger, Cornelis JM Melief, Daniel J Powell, David F Stroncek, DG Song, DJ Powell Jr, DL Porter, Francesco M Marincola, G Mostoslavsky, GG Kenter, Gustavo Mostoslavsky, J Jin, J Staerk, James R Heath, Jeffrey S Miller, JN Kochenderfer, JN Kochenderfer, John O'Shea, JS Miller, K Takahashi, L Gattinoni, L Gattinoni, L Gattinoni, L Gattinoni, LA Johnson, Luca Gattinoni, M Kalos, M Kalos, M Kalos, Mahendra Rao, Mark E Dudley, Martin A Cheever, ME Dudley, ME Dudley, Michael Kalos, Nicholas P Restifo, P Muranski, Peter Flynn, PF Robbins, RA Morgan, Richard W Childs, SA Rosenberg, Steven A Rosenberg, TS Park, X Wang   +48 more
core   +4 more sources

CAR-T cell a potential platform for cancer therapy

Medicine in Novel Technology and Devices
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a viable treatment for various types of cancers, including B-cell lymphoma and leukemia. CAR-T cells use genetically engineered T lymphocytes that are retargeted to destroy cancer cells using ...
Azad Kumar Maurya, Shivani Saraf, Laxmikant Gautam, Rajeev Sharma   +3 more
doaj   +1 more source

Treatment of Adult Patients with Relapsed/Refractory B-Cell Philadelphia-Negative Acute Lymphoblastic Leukemia [PDF]

, 2019
The majority of adult patients affected by B-cell acute lymphoblastic leukemia (B-ALL) will relapse after an initial response, while approximately 20% will display primary resistant disease. Patients suffering from relapsed/refractory B-ALL have a very
Lanza, Francesco, Maffini, Enrico, Saraceni, Francesco   +2 more
core   +1 more source

Adoptive Cellular Therapy in Acute Myeloid Leukemia: Current Scope and Challenges

Hematology/Oncology and Stem Cell Therapy, 2022
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in ...
Sankalp Arora, Palash Asawa, Aravind Ramakrishnan, Carlos Bachier, Navneet S. Majhail   +4 more
doaj   +1 more source

Stem-cell-based gene therapy for HIV infection. [PDF]

, 2013
Despite the enormous success of combined anti-retroviral therapy, HIV infection is still a lifelong disease and continues to spread rapidly worldwide. There is a pressing need to develop a treatment that will cure HIV infection.
Kitchen, Scott, Zhen, Anjie
core   +2 more sources

Generation of an anti-CD19 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology

Stem Cell Research
Chimeric antigen receptor T cell (CAR-T) therapy represents a major breakthrough in the field of tumor immunotherapy. CD19-targeted CAR-T cells (CD19 CAR-T) have emerged as an important therapeutic approach for treating B-cell malignancies.
Shuoting Wang, Yashu Feng, Qi Xing, Tiancheng Zhou, Jiajun Liu   +4 more
doaj   +1 more source

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy. [PDF]

, 2018
Malignant gliomas carry a dismal prognosis. Conventional treatment using chemo- and radiotherapy has limited efficacy with adverse events. Therapy with genetically engineered T-cells, such as chimeric antigen receptor (CAR) T-cells, may represent a ...
Almeida, Neil D, Chuntova, Pavlina, Downey, Kira M, Hegde, Bindu, Okada, Hideho   +4 more
core  

From Bench to Bedside: Emerging Paradigms in CAR‐T Cell Therapy for Solid Malignancies

Advanced Science
Immunotherapy, particularly chimeric antigen receptor T cell (CAR‐T) therapy, has revolutionized the treatment of hematological malignancies and autoimmune diseases.
Yang Chen, Ran Ren, Lirong Yan, Yu Zhou, Ruokai Sun, Huicong Song, Hongfei Yan, Yongsheng Li   +7 more
doaj   +1 more source

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

Huli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

Nature Communications, 2020
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in ...
Hsiang-chi Tseng, Wei Xiong, Saiaditya Badeti, Yan Yang, Minh Ma, Ting Liu, Carlos A. Ramos, Gianpietro Dotti, Luke Fritzky, Jie-gen Jiang, Qing Yi, James Guarrera, Wei-Xing Zong, Chen Liu, Dongfang Liu   +14 more
doaj   +1 more source